Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC.
Zelikson V, et al. Among authors: winter a.
Haematologica. 2024 Nov 14:0. doi: 10.3324/haematol.2024.285977. Online ahead of print.
Haematologica. 2024.
PMID: 39540227
Free article.